Literature DB >> 8999898

Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation.

S Aizawa1, H Nakano, T Ishida, R Horie, M Nagai, K Ito, H Yagita, K Okumura, J Inoue, T Watanabe.   

Abstract

Signals emanated from CD30 can activate the nuclear factor kappaB (NFkappaB). The two conserved subdomains, D1 and D2, in the C-terminal cytoplasmic region of CD30 were tested for interaction with two tumor necrosis factor receptor-associated factor (TRAF) proteins with NFkappaB activating capacity, TRAF2 and TRAF5. TRAF5 is the newest member of the TRAF family that binds to lymphotoxin beta receptor and CD40. TRAF5, as well as TRAF2, interacted with the D2 subdomain of CD30 in vitro and in vivo. Deletion analysis by the yeast two-hybrid system revealed that the C-terminal 22 and 30 amino acid residues are dispensable for interaction of TRAF5 and TRAF2 with CD30, respectively. Substitution of alanine for threonine at 463 abolished the interaction with TRAF2. Overexpression of the TRAF domain of TRAF2 or TRAF5 showed a dominant negative effect on CD30-mediated NFkappaB activation. Simultaneous expression of these TRAF domains further suppressed the NFkappaB activation, suggesting an interplay of these TRAF proteins. Expression of TRAF2 and TRAF5 mRNA was demonstrated in T- and B-cell lines that express CD30. Taken together, our results indicate that TRAF2 and TRAF5 directly interact with CD30 and are involved in NFkappaB activation by CD30 signaling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8999898     DOI: 10.1074/jbc.272.4.2042

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.

Authors:  Ryouichi Horie; Takuro Watanabe; Kinji Ito; Yasuyuki Morisita; Mariko Watanabe; Takaomi Ishida; Masaaki Higashihara; Marshall Kadin; Toshiki Watanabe
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 3.  Prognostic factors in pediatric Hodgkin disease.

Authors:  Cindy L Schwartz
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

4.  Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

Authors:  R Horie; V Gattei; K Ito; S Imajo-Ohmi; T Tange; J Miyauchi; A Pinto; M Degan; A De Iuliis; F Tassan Mazzocco; F M Rossi; M Higashihara; T Watanabe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

5.  The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 6.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 7.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

8.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

Review 9.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

10.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.